Multiple system atrophy: 2026 so far

In the months covered, one trial was clearly negative, and another report raised a possible liver-injury signal.

In the months covered, the clearest disease-modifying-style result was negative. The phase 2 amlenetug antibody trial did not meet its prespecified endpoint for slowing UMSARS progression versus placebo over 72 weeks. Safety was described as generally comparable between groups, with frequent side effects reported in both groups (2026-4). Later, a separate phase 2 randomized trial of KM-819 reported suspected drug-induced liver injury in treated participants (11/34; 9 adjudicated related) and none in placebo. It also reported a small exploratory HLA signal (a genetic marker related to immune response) that the authors said needs confirmation (2026-9). Taken together, these reports mean that one alpha-synuclein antibody approach did not clear its trial bar, and that the KM-819 trial raised a specific liver-safety concern.

Research covered in: April 2026, September 2026

The evidence base grew, from pooled rTMS trials to a short tACS randomized trial.

So far in 2026, non-drug neuromodulation (using electrical or magnetic stimulation to influence brain activity) was studied several times for symptom relief. A systematic review pooling six randomized controlled trials (140 people with MSA) reported that rTMS (repetitive transcranial magnetic stimulation, a noninvasive magnetic brain stimulation) improved ataxia (problems with coordination) and motor function. It also reported improvements in anxiety, depression, and fatigue scores. The authors noted that more randomized trials are needed to confirm how reliable and long-lasting these effects are (2026-7). A separate randomized, double-blind, placebo-controlled trial in MSA-C (the cerebellar subtype of MSA) found that 2 weeks of daily tACS (transcranial alternating current stimulation, gentle electrical stimulation through the scalp) improved UMSARS score versus sham. It also improved ataxia and gait measures. No treatment-related serious side effects were reported over the short study period (2026-9). In these reports, brain stimulation was linked to measurable short-term changes in movement (and some non-motor symptoms for rTMS), but it was still not clear how long benefits last or which people are most likely to respond.

Research covered in: July 2026, September 2026

A small randomized posture study showed targeted effects, while an exploratory medication study had mixed results.

In the available months, supportive care for blood pressure instability included one small randomized trial and one exploratory drug study. A randomized trial (20 people with Parkinson's disease or MSA) found that whole-bed head-up tilt (raising the head of the bed) improved several daytime and standing blood pressure measures. It did not lower nighttime systolic blood pressure. Adherence dropped at steeper tilt angles (2026-5). Separately, an exploratory two-phase ampreloxetine study in MSA with symptomatic neurogenic orthostatic hypotension (low blood pressure on standing due to nerve control problems) did not meet its primary endpoints. Symptoms stayed stable on drug and worsened after randomized withdrawal to placebo on several measures. Standing blood pressure fell after placebo withdrawal, and the report did not observe increases in supine blood pressure (high blood pressure while lying flat) (2026-7). In these reports, posture-based strategies showed specific blood pressure improvements but came with real-world limits on how well people could stick with them, while medication evidence remained uncertain because the primary endpoints were not met despite signals seen during withdrawal.

Research covered in: May 2026, July 2026

Reports moved from mixed-diagnosis PEG data to a matched analysis focused on MSA.

In January 2026 to September 2026, swallowing-related supportive care came up repeatedly. The reports linked some interventions to survival, but they also left important trade-offs unclear. Early in the year, a retrospective international cohort across atypical parkinsonian conditions (including MSA) found that PEG feeding tube placement (a tube placed into the stomach for nutrition) was linked to longer survival from dysphagia onset (trouble swallowing). It did not clearly reduce aspiration pneumonia hospital admissions (lung infection from food or liquid going into the airway) (2026-1). Later, a single-center retrospective MSA cohort (with propensity-score matching, a method to make comparison groups more similar) reported longer survival with enteral nutrition (nutrition delivered through the gut) (restricted mean survival time difference 0.68 years) and fewer sudden deaths. It also reported a higher incidence of tracheostomy or tracheostomy invasive ventilation over time, and it did not include quality-of-life data (2026-9). In these reports, tube feeding and related airway-focused pathways were being studied as later-stage options with possible links to survival, while effects on aspiration risk, comfort, and communication were not settled.

Research covered in: January 2026, September 2026

In the months covered, multi-test diagnosis became more common, and a large study supported blood NfL.

In the months covered, diagnostic research repeatedly favored combining complementary tests instead of relying on a single marker. Reports evaluated alpha-synuclein assays (tests that look for abnormal alpha-synuclein protein), imaging panels (sets of scans read together), and blood markers (2026-1, 2026-2, 2026-3, 2026-4, 2026-5, 2026-6, 2026-7, 2026-8, 2026-9). The strongest single near-term separator reported was blood neurofilament light chain (NfL). A multicentre diagnostic study of 2408 people found that NfL separated MSA from Parkinson's disease well, including in an early-stage subgroup (AUC 0.943). Adding GFAP/total tau/p-tau217 only slightly changed performance (2026-8). At the same time, multiple reports emphasized that alpha-synuclein seed amplification results (tests that try to amplify tiny amounts of misfolded protein to detect disease) can vary by lab method. This included a multicenter comparison where one condition did not detect MSA and agreement between methods was low for MSA. Reports also noted that skin biopsy approaches (testing a small skin sample for disease-related protein changes) can influence real-world diagnostic labeling but do not solve diagnosis for everyone (2026-2, 2026-5, 2026-9). In these reports, diagnostic confidence increasingly depended on patterns across multiple tests, with NfL looking especially strong as a blood-based discriminator in one large dataset while other assays still faced standardization and validation hurdles.

Research covered in: January 2026, February 2026, March 2026, April 2026, May 2026, June 2026, July 2026, August 2026, September 2026